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Editorial on the Research Topic
The Role of Optineurin in Immunity and Immune-Mediated Diseases
The multifunctional adaptor optineurin has been implicated in an increasing number of protein-
protein interactions and cellular functions ever since its first identification as a binding partner
for an adenoviral protein (1). Most—if not all—optineurin functions require its ubiquitin-binding
domain in its C-terminus, which binds to K63- and/or M1-polyubiquinated proteins, allowing it to
act, for example, as an adaptor during inflammatory signaling, autophagy, and vesicle trafficking
(2–4). The interest in optineurin intensified after the identification of various mutations and
polymorphisms in several human diseases, including primary open-angle glaucoma, amyotrophic
lateral sclerosis (ALS), Paget’s disease of the bone, and Crohn’s disease. With their distinct yet
unresolved pathogenesis, and complex genetic and environmental risk factors, these diseases seem
unrelated at first. ALS, glaucoma, or Paget’s disease are not traditionally regarded as immune-
mediated diseases; however, the emerging evidence pinpoints immune system disfunction as their
common denominator (5, 6). The aim of this Research Topic was to explore the role(s) of optineurin
on a host of diverse cellular pathways that are directly or indirectly linked to the immune response.
The articles cover immune signaling, cell death, membrane trafficking, autophagy of intracellular
bacteria (xenophagy), damaged mitochondria (mitophagy), and protein aggregates.
In their mini review, Slowicka and van Loo give an overview of the various lines of evidence
implicating optineurin in the regulation of the immune response. Due to its high homology to the
NF-κB essential modulator (NEMO), optineurin was initially considered to be a negative regulator
of NF-κB, a major proinflammatory transcription factor (7, 8). However, NF-κB hyperactivation
was not identified in a range of primary cells from loss-of-function optineurin mouse models
(9–12). This unexpected finding is further analyzed by Liu et al. through an investigation of the
overexpression of the common optineurin ALS mutations in mouse embryonic fibroblasts; this is
demonstrated to lead to higher NF-κB activation and inflammatory cytokine secretion. They follow
this up by delivering lentiviruses carrying patient ubiquitin-binding deficient E478G mutation
or wild-type optineurin into the mouse motor cortex, showing that expression of the mutant
optineurin triggers immune cell infiltration, microgliosis, proinflammatory cytokine secretion, and
impaired motor functions. Outlioua et al. review the role of optineurin in regulating antiviral
type I interferon (IFN) production through activation of TANK-binding kinase 1 (TBK1) at
the Golgi apparatus. TBK1 is K63-polyubiquitinated upon pathogen or damage-sensing, which
allows TBK1 to be recognized and to dock onto optineurin by a bipartite interaction via its
ubiquitin-binding site and coiled-coil regions. Optineurin thereby serves as an adaptor for TBK1
trans-autophosphorylation and activation. The authors also emphasize that the interaction between
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optineurin and TBK1 is multifaceted as optineurin itself
becomes phosphorylated by TBK1, which is crucial for its
role as an autophagy receptor and to its interaction with the
microtubule-associated protein 1A/1B light chain 3B (LC3) in
autophagosomal membranes.
Several publications elaborate on the role of optineurin in
autophagy, which extends beyond its function as an autophagy
receptor for the recruitment of LC3-positive membranes to
ubiquitinated cargo. The central role of optineurin in diverse
membrane trafficking pathways (autophagosome-lysosome
fusion, vesicle secretion, etc.) and the importance of different
binding partners is comprehensively summarized by Ryan and
Tumbarello. This review specifically highlights the central role
of optineurin in selective autophagy and how its disfunction is
linked to neuronal cell death and neurodegeneration. Weil et al.
have compiled an extensive review on mitophagy and the role
of optineurin in mitochondrial regulation and its implications
in neurodegeneration and cancer. Abnormalities in mitophagy
are associated with a number of diseases, including Parkinson’s
disease, ALS, primary open angle glaucoma, and cancer. The
current understanding on how optineurin mutations found in
ALS and glaucoma impact on mitophagy are covered in the
manuscript. Finally, the authors discuss whether the potential
role of optineurin in mitophagy is also linked to other diseases,
such as cancer and inflammatory bowel disease.
Toth and Atkin focus their review initially on the multiple
cellular mechanisms of optineurin, and they then proceed to
put these processes in context with ALS and glaucoma. Disease-
associated optineurinmutations and the impact these have on the
physiological processes of inflammatory signaling, endoplasmic
reticulum stress, secretion, autophagy, and cell viability are
discussed in detail. The review highlights the complexity of
neurodegeneration and how optineurin in combination with
other key disease-associated molecules, such as SOD1 and TBK1,
is thought to contribute to disease progression. The review
by Swarup and Sayyad specifically highlights the link between
optineurin and glaucoma. The authors discuss the impact of
the glaucoma-associated mutants, the E50K and M98K, on the
cellular functions of optineurin. Interestingly, these glaucoma-
specific mutations induce pathologies only in retinal cells
despite optineurin being widely expressed in different cell types
and tissues.
Tschurtschenthaler and Adolph’s mini review brings together
the current literature dealing with optineurin and intestinal
inflammation and places them in the context of Crohn’s disease
etiology. Optineurin has been reported to play a major role in
xenophagy, the regulation of endoplasmic reticulum stress, and
the facilitation of pro-inflammatory cytokine secretion, all of
which have a major impact on the intestine and have previously
been associated with the development of Crohn’s disease (13).
The review covers findings from a number of studies that support
an active role for optineurin in intestinal immunity and describe
the chronic bowel inflammation that develops in its absence.
Finally, they describe how optineurin limits the accumulation of
an endoplasmic reticulum-anchored inflammatory signaling hub
within the intestinal epithelium, which prevents the development
of spontaneous enteritis. The precise role of optineurin in
Crohn’s disease is still unclear, and the authors thus highlight the
need for further investigation.
This collection highlights the wide range of functions
associated with optineurin, many of which are crucial for
maintaining tissue homeostasis by use of the innate immune
system. This may explain why optineurin mutations are
found in a wide array of chronic disorders. Many open
questions remain, especially whether optineurin mutations
and/or polymorphisms found in patients act as primary or
contributing factors in disease pathogenesis. We hope that
further insight into how the mechanisms by which optineurin
loss- and/or gain-of-function causes different disorders will incite
new immunomodulatory therapies.
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